Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance
Date:8/7/2009

p>Based on the year-to-date results and current outlook for the remainder of 2009, the Company is affirming its full year 2009 revenue guidance. For 2009, the Company continues to anticipate revenue to be in the range of $1,015 to $1,025 million.

Based on the current and forecasted mix of products sold, the Company is raising its guidance on gross margin as a percentage of total revenue to a range of 80% to 81%. This reflects of the Company's current expectation that a favorable product mix will continue to benefit its overall margins.

The Company is updating its expected ranges for certain operating expense items for the full year 2009. Total anticipated SG&A expenses continue to be in the range of $203 to $212 million, as expected reductions in A&P expenses should offset expected increases in G&A expenses. More specifically, A&P expenses are expected to be in the range of $38 to $41 million which reflects our current expectations of promotional spending by our sales forces. G&A expenses are expected to be in the range of $81 to $84 million, which reflects an increase to previously estimated professional and legal fees. R&D spend is now expected to be in the range of $72 to $75 million rather than $77 to $80 million. The decrease is reflective of reduced estimates of ongoing R&D study expenses primarily due to changes to the expected timing of expenditures.

Based on the above revisions, the Company is now anticipating CNI per share to be $0.05 per share higher than previously forecasted. The Company anticipates CNI per share to in the range of $1.60 to $1.65.

The Company's full year 2009 revised guidance is summarized on the last exhibit to this release.

Investor Conference Call

The Company is hosting a conference call open to all interested parties, on Friday, August 7, 2009 beginning at 8:00 AM EDT. The number to call wit
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
6. Warner Chilcott Announces 2008 Financial Guidance
7. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
10. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
11. Warner Chilcott Announces Settlement of Securities Litigation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Slate and New Markets build o...ness services sector. , B...apital Group ( www.slatecap.com ), a private equit...ts Venture Partners ( www.newmarketsvp.com ), a ve..., today announced that they have acquired Ecoast S...
(Date:11/24/2009)... Tattoo Removal Laser Clinic, ...e in America, Corporal Jason, with his new modelin...he time he begins modeling full time in the middle... November 24, 2009 -- Tattoo Removal Laser Clinic,...ne in America, Corporal Jason, with his new modeli...
(Date:11/23/2009)...earchers from the University of Michigan determine...on Americans with hepatitis C virus (HCV) infectio.... Treatment rates appear to be declining, in part...nfected. If this disturbing trend continues, by 2... will be prevented by antiviral therapy. This stu...
(Date:11/23/2009)... Same Day STD Testing now prov...for all types of STD,s, including Chlamydia, Herpe... all done anonymously. , ...found on the web at: http://www.samedaystdtesting...tial STD testing, which is now available to accura...
(Date:11/23/2009)..., HATBORO,Pa.,Nov.23/PRNewswire-FirstCall/--InfoL...rofenterprisemobilitysolutionsforthehealthcareandc...rVicePresidentofManagedServicesatSiemensHealthServ...ealthcareServices. ,, (Logo: http://www.newscom...icePresidentofStrategicHealthcareServicesforInfoLo...
Breaking Medicine News(10 mins):Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 2Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 3Health News:Tattoo Removal on the Fastest U.S. Marine 2Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:100% Anonymous, Confidential and Quick STD Screening Now Available with Same Day STD Testing 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3
...ider updates 44 courses and develops 20 for,employ...rchair,Learning Systems (SLS), the leader in senio...d expanded its course offerings. As part of its no...ior care market," said Mike Benzian, President of ...
... 13 Animal shelters house,abandoned older pets, w...n,favor of younger, playful puppies and kittens. ...ted to the life these,older pets have left to live... Hinton, former Kentucky Humane Society director,a...
...VE Nutrition,International Inc., a subsidiary of N...http://www.naturalnutritioninc.com has made anoth...by shipping its first nutritional,supplement order...cant achievement, according to the export division...
...raphy or PET scans can help clinicians diagnose an...her the imaging technology helps people with cance...comprehensive review by the U.K. National Health S...r imaging technologies such as computerized tomogr...
... 12 NightHawk,Radiology Holdings, Inc. (Nasdaq: ...s to radiology groups and hospitals throughout the...t at the 19th Annual Piper Jaffray,Healthcare Conf... Chief Financial Officer, will share information,a...
...India, Nov. 12 ,Seeking to expand Indo-U.S. health...s (USIBC) Coalition for Healthy India launched its... is comprised of executives from the,most prominen...BD, Yes Bank, Patton Boggs, Ernst & Young, the,Ass...
Other Medicine News:Health News:Silverchair Learning Systems Updates and Develops New Courses 2Health News:Old Dogs Can Learn New Tricks 2Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Panama 2Health News:PET scans useful for some cancer treatment, but how do patients fare? 2Health News:NightHawk Radiology Holdings, Inc. to Speak at Annual Piper Jaffray Healthcare Conference on November 28, 2007 2Health News:USIBC Launches Healthcare Mission to India 2
(Date:11/23/2009)...LASVEGAS,Nov.23/PRNewswire-FirstCall/--CordBloodAm...bloodstemcellpreservationcompany( http://www.cordb...tentialofstemcells,abiologicalinsurancepolicy,tofa...hatanupdatedprogressinterviewwithCEOandco-founderM...rviewisat: http://blip.tv/file/2875811 . ,, Int...
(Date:11/23/2009)...PRINCETON,N.J.,Nov.23/PRNewswire-FirstCall/--Pharm...llmentofCohort2,ledbyitspartnerRoche(SWX:ROG.VX;RO...type1and4patientsintheongoingphase2btrialofRG7128,...forthetreatmentofchronichepatitisCvirus(HCV)infect...independentDataMonitoringCommittee(DMC)ofallavaila...
(Date:11/23/2009)...NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/--Raptor...: RPTP ),todayannouncedresultsfromaPhase2bclinical...rtrate("DRCysteamine")inpatientswithnephropathiccy...ersityofCalifornia,SanDiego("UCSD")GeneralClinical...cokineticsandpharmacodynamicsofasingledoseofDRCyst...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5AFB Senior Site Offers New Information to Help Senior Citizens Manage Diabetes and Vision Loss 61313 1AFB Senior Site Offers New Information to Help Senior Citizens Manage Diabetes and Vision Loss 61313 2AFB Senior Site Offers New Information to Help Senior Citizens Manage Diabetes and Vision Loss 61313 3AFB Senior Site Offers New Information to Help Senior Citizens Manage Diabetes and Vision Loss 61313 4Misonix Announces New Distribution Agreement For The United Arab Emirates 28UAE 29 6255 1Misonix Announces New Distribution Agreement For The United Arab Emirates 28UAE 29 6255 2Misonix Announces New Distribution Agreement For The United Arab Emirates 28UAE 29 6255 3Custom Spine Launches Pathway AVID and Regent ACP at NASS 6251 1Custom Spine Launches Pathway AVID and Regent ACP at NASS 6251 2
...in sodium injection) were also less likely ...DGEWATER, N.J., Dec 10 Sanofi-aventis,announced t...l hospital,direct medical costs associated with VT...hey were treated with the use of low-molecular wei...) with 97.3% of LMWH patients,receiving Lovenox. P...
...ced leukemia and myelodysplastic, syndrome patien...eting., PRINCETON, N.J., Dec. 10 Celator Pharmac...hase I study of CPX-351, a liposomal,formulation t... and,daunorubicin for the treatment of advanced le...escalation in the study is ongoing, thus far three...
Other Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients 2